240 related articles for article (PubMed ID: 30578715)
1. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B.
Zhou L; Li X; Huang X; Chen L; Gu L; Huang Y
J Viral Hepat; 2019 Jul; 26(7):795-802. PubMed ID: 30578715
[TBL] [Abstract][Full Text] [Related]
2. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment.
Xia J; Huang R; Chen Y; Liu Y; Wang J; Yan X; Zhang Z; Wu C
Aliment Pharmacol Ther; 2020 Jun; 51(11):1180-1187. PubMed ID: 32363582
[TBL] [Abstract][Full Text] [Related]
3. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment.
Tan N; Luo H; Kang Q; Pan J; Cheng R; Xi H; Chen H; Han Y; Yang Y; Xu X
Virus Res; 2022 Feb; 309():198660. PubMed ID: 34929214
[TBL] [Abstract][Full Text] [Related]
4. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L
Gene; 2022 Jan; 806():145935. PubMed ID: 34478821
[TBL] [Abstract][Full Text] [Related]
5. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B.
Demirören K; Kocamaz H; Doğan Y
Turk J Gastroenterol; 2015 Jan; 26(1):36-41. PubMed ID: 25698269
[TBL] [Abstract][Full Text] [Related]
6. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
7. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
Li J; Sun X; Fang J; Wang C; Han G; Ren W
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
[TBL] [Abstract][Full Text] [Related]
8. Association between serum platelet-derived growth factor BB and degree of liver damage, fibrosis and hepatitis B e antigen (HBeAg) status in CHB patients.
Diang XC; Ma LN; Li YF; Liu XY; Zhang X; Liu JY; Sheng YJ; Zhang DZ; Hu HD; Ren H
Hepatogastroenterology; 2012; 59(120):2357-60. PubMed ID: 22688015
[TBL] [Abstract][Full Text] [Related]
9. [Value of non-invasive models of liver fibrosis in judgment of treatment timing in chronic hepatitis B patients with ALT < 2×upper limit of normal].
Zhou QQ; Hu YB; Zhou K; Zhang WW; Li MH; Dong P; Di JG; Hong L; Du QW; Xie Y; Sun QF
Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):665-670. PubMed ID: 27788722
[No Abstract] [Full Text] [Related]
10. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase.
Zhou J; Song L; Zhao H; Yan L; Ma A; Xie S; Zhang X; Zhang D; Xie Q; Zhang G; Shang J; Cheng J; Zhao W; Zou Z; Zhang M; Xia N; Wang G
Sci Rep; 2017 Jun; 7(1):2747. PubMed ID: 28584279
[TBL] [Abstract][Full Text] [Related]
11. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z
Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110
[TBL] [Abstract][Full Text] [Related]
13. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
[TBL] [Abstract][Full Text] [Related]
14. [Significance of soluble PD-L1 in patients with chronic hepatitis B and hepatitis C].
Ke RM; Ouyang LJ; Li WF; Peng XM
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):133-137. PubMed ID: 37137827
[No Abstract] [Full Text] [Related]
15. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B.
Jiang C; Liu J; Li R; Chen K; Peng W; Fu L; Peng S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):698-706. PubMed ID: 37539572
[TBL] [Abstract][Full Text] [Related]
17. Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection.
Zeng DW; Liu YR; Dong J; Zhu YY; Li YB; Chen J; Zheng Q; Jiang JJ
Mol Med Rep; 2015 May; 11(5):3465-72. PubMed ID: 25592612
[TBL] [Abstract][Full Text] [Related]
18. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.
Yan JY; Li ZQ; Yu ZJ; Kan QC
J Cell Biochem; 2019 Apr; 120(4):6632-6641. PubMed ID: 30368885
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
[TBL] [Abstract][Full Text] [Related]
20. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
